

Supporting Information

**CTL-Doxorubicin (DOX)-Gold complex Nanoparticles
(DOX-AuGCs): From Synthesis to Enhancement of Therapeutic Effect on Liver Cancer Model**

Quiqian Liu^{1‡}, Hui Liu^{2‡}, Pasquale Sacco³⁻⁴, Nadia Djaker¹, Marc Lamy de la Chapelle⁵,
Eleonora Marsich³⁻⁴, Xiaowu Li^{2*}, Jolanda Spadavecchia^{1-2*}

¹ CNRS, UMR 7244, NBD-CSPBAT, Laboratoire de Chimie, Structures et Propriétés de Biomatériaux et d'Agents Thérapeutiques Université Paris 13, Sorbonne Paris Nord, Bobigny, France

² Department of hepato-biliary surgery, Shenzhen University General Hospital & Guangdong Provincial Key Laboratory of Regional Immunity and Diseases & Carson International Cancer Shenzhen 518055, China

³ Department of Life Sciences, University of Trieste, Via L. Giorgieri 5, I-34127 Trieste, Italy

⁴ Department of Medicine, Surgery and Health Sciences, University of Trieste, Piazzale Europa 1, I-34127 Trieste, Italy

⁵ IMMM – UMR 6283 CNRS, Université du Mans, Avenue Olivier Messiaen, 72085 Le Mans, Cedex 9, France

Corresponding Author*: lixw1966@163.com; jolanda.spadavecchia@univ-paris13.fr

Table S1: z-potential and hydrodynamic diameter of **DOX AuGCs**.

Synthetic product	Zeta potential (mV)	Hydrodynamic diameter (nm)	PdI
DOX AuGCs	-31,4±1,06	50 ± 3	0,259±0,002




Figure S1. UV-Vis spectra of DOX-AuGCs in DMEM as function of time (black spectrum: 0 h, red spectrum: 48 h, blue spectrum: 72 h, green spectrum: 144 h)




Figure S2. (a) Percentage (%) of DOX released from DOX-AuGCs overtime in PBS (37 °C) at pH 7 (red curve) and 5 (black curve). Data are reported as average \pm standard deviation. (b) Schematic diagram of DOX release under acidic conditions.













Figure S 3. Morphology of the tumor (A) and spleen tissues (B) of each group taken out from the sacrificed mice at the study end point.








Figure S4. Effects of DOX-AuGCs on blood cells. The statistical significance was determined by the paired Student *t*-test (**P* < 0.05).





Figure S5. Effect of DOX-AuGCs on serum level of GM-CSF. The statistical significance was determined by the paired Student *t*-test (**P* < 0.05).



Scheme S1. Schematic hypothesis of cardiotoxicity inhibition from DOX AuGCs complex